GEN Exclusives

More »

GEN Poll

May 28, 2012

Biotech M&A in 2012

The bad news for the IPO market should mean good news for biotechnology M&As in 2012, and for the most part it does. However, premiums or multiples paid per deal vary significantly, with big companies increasingly willing to pay a big price for an increased presence in selected areas, notably specialty pharma and diagnostics. Not all deals go through, as the unsuccessful Roche-Ilumina and GSK-HGS courtships can attest. Experts expect M&As to continue the brisk pace of recent months through the rest of 2012.

What is your forecast for mergers and acquisitions this year?

Sunny and hot
Partly cloudy and lukewarm
Cloudy and cool

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »